Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematosus and Systemic Sclerosis Tissues
2022-001484-27Phase 2Completed
- Sponsor
- Radboudumc
- Start
- Oct 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zirconium-89 crefmirlimab berdoxam in cutaneous lupus erythematosus (CLE), Sjögren's syndrome and systemic sclerosis (SSc), sponsored by Radboudumc. Primary endpoint: Difference in differentiation, activation and regulation of expanded B and T cell clones between tissues and diseases. Started Oct 2022; status: completed.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
cutaneous lupus erythematosus (CLE)Sjögren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2022-001484-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001484-27.